The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that increases blood flow, inhibits apoptosis, and induces neurovascular remodeling WILLOWBROOK, Ill., May 31, […]
Tag: Pharmazz
Pharmazz, Inc. Announces US FDA Clearance for a Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke Patients
The primary endpoint is the proportion of patients with a good outcome as a modified Rankin Score (mRS) of 0-2 on day 90 post-randomization Sovateltide is an endothelin-B receptor agonist that has been shown to increase blood flow, inhibit apoptosis, […]
Pharmazz Inc. Announces Positive Results of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke
Sovateltide produced a statistically significant and clinically meaningful improvement in neurological outcomes in acute cerebral ischemic stroke patients 90 days post-treatment Sovateltide demonstrated a highly favorable ordinal shift in the modified Rankin Scale (mRS) score and a significantly (p=0.0045) greater number of […]
Pharmazz Inc. Announces Completion of Enrollment of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke
Sovateltide is an endothelin B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling WILLOWBROOK, Ill., Feb. 17, 2022 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing […]